These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 444377)

  • 1. Influence of renal failure on disopyramide pharmacokinetics [proceedings].
    Henry JA; Johnston A; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1979 Apr; 7(4):427P-428P. PubMed ID: 444377
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disopyramide in renal impairment.
    Whiting B; Elliott HL
    Lancet; 1977 Dec 24-31; 2(8052-8053):1363. PubMed ID: 74774
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
    Ashford JJ; Carmichael D; Kidner PH
    Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.
    Hinderling PH; Garrett ER
    J Pharmacokinet Biopharm; 1976 Jun; 4(3):199-230. PubMed ID: 978389
    [No Abstract]   [Full Text] [Related]  

  • 8. Disopyramide pharmacokinetics and bioavailability.
    Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
    Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of Norpace.
    Karim A
    Angiology; 1975 Jan; 26(1 Pt 2):85-98. PubMed ID: 1090217
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dosage of disopyramid in insufficient renal function].
    Burk M; Peters U; Risler T; Grabensee B
    Med Welt; 1982 Dec; 33(49):1789-91. PubMed ID: 7162399
    [No Abstract]   [Full Text] [Related]  

  • 14. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
    Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
    J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
    [No Abstract]   [Full Text] [Related]  

  • 16. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide pharmacokinetics during recovery from myocardial infarction.
    Bryson SM; Cairns CJ; Whiting B
    Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic study of disopyramide in normal man].
    Mallein R; Rondelet J; Boucherat M; Ksavrelof M; Pignat M
    Therapie; 1978; 33(4):463-73. PubMed ID: 734626
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].
    Witkowska M
    Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.